Press Releases | Alexion Pharmaceuticals, Inc

About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
- North America
  - Canada
  - USA
- Latin America
  - Argentina
  - Brazil
  - Colombia
  - Mexico
- Europe, the Middle East & Africa
  - Alexion Europe
  - Belgium
  - Denmark
  - France
  - Germany
  - Ireland
  - Italy
  - Netherlands
  - Norway
  - Russia
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - UAE
  - UK
- Asia Pacific
  - Australia
  - China
  - India
  - Japan
Investors
News
Contact

Home
»
Newsroom
»
Press Releases

Press Releases

All News Releases

Alexion Announces Creation of New Roles on Executive Leadership Team
February 12, 2019
HTML PDF
Alexion Reports Fourth Quarter and Full Year 2018 Results
February 4, 2019
HTML PDF
Alexion to Highlight Rare Disease Portfolio at Investor Day
February 1, 2019
HTML PDF
Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis
January 31, 2019
HTML PDF
Alexion Announces Positive Top-Line Results from Phase 3 Study of ULTOMIRIS™ (Ravulizumab-cwvz) in Complement Inhibitor-Naïve Patients with atypical Hemolytic Uremic Syndrome (aHUS)
January 28, 2019
HTML PDF
Alexion to Report Fourth Quarter and Full Year 2018 Results on Monday, February 4, 2019
January 7, 2019
HTML PDF
Alexion to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 2, 2019
HTML PDF
Alexion to Present at the Goldman Sachs 11th Annual Healthcare CEO Conference
December 21, 2018
HTML PDF
Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
December 21, 2018
HTML PDF
Comprehensive Positive Phase 3 Data for Alexion’s ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood
December 3, 2018
HTML PDF